Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
MYC is an iconic oncogene that has been at the forefront of cancer research since its discovery. Looking back over the history of MYC research provides us with a framework with which to progress in the next 25 years, as outlined in this Timeline.
Anti-angiogenic drugs have become part of the standard therapeutics used to treat cancer. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles. Will other agents with complementary mechanisms offer novel opportunities for improved treatment?
Insulin and insulin-like growth factors (IGFs) are well-known as key regulators of energy metabolism and growth and have important roles in neoplasia. This Review documents the various methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signalling.
DNA double strand breaks (DSBs) may lead to cancer but, paradoxically, are also used to kill cancer cells. How might γH2AX — a surrogate marker of DSBs — be used to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs?
The disintegrin metalloproteinases of the Adam (a disintegrin and metalloproteinase) family mediate proteolytic 'shedding' of membrane-associated proteins and hence rapidly modulate key cell signalling pathways in the tumour microenvironment. What is the biological and clinical relevance of the ADAMs?
Increased RNA polymerase III activity in cancer has been observed for over 30 years but how this occurs and affects cellular transformation is only beginning to be understood. Lynne Marshall and Robert J. White discuss recent progress made in this emerging field.
During the past century, the response to hypoxia has emerged as an important phenotypic determinant of a tumour, with repercussions for sensitivity to radiation and chemotherapy. This Timeline provides a historical overview of responses to hypoxia while looking forward to therapeutic strategies that are being developed to exploit them.
